Envisagenics Inc

Envisagenics Inc. is a privately held company based in Long Island City, New York. Founded in 2014 as a spinout of Cold Spring Harbor Laboratory, the company employs 49 people and generates approximately $11 million in annual revenue. Envisagenics specializes in the discovery of RNA therapeutics. They focus on addressing genetic diseases and cancers potentially caused by mutations affecting RNA splicing. The company's technology, SpliceCore, is a cloud-based platform that utilizes artificial intelligence to analyze RNA sequencing data and predict drug targets and biomarkers. SpliceCore is experimentally validated and aims to revolutionize the drug development process by identifying splicing errors linked to diseases, pinpointing potential drug targets, and accelerating the development of RNA therapeutics. This in-silico platform aims to reduce the time, cost, and risk associated with traditional drug development by replacing expensive and time-consuming experimental processes with efficient computer simulations. For more information about Envisagenics and its innovative RNA therapeutics platform, visit their website at envisagenics.com.